Strides Pharma FY25 dividend: ₹4/share after profit jump

The dividend declared in the current financial year

Strides Pharma Science Ltd has declared a dividend of ₹4.00 per share in the current financial year, with the declaration dated 22 July 2025. The dividend relates to FY25, following the company’s full-year and March-quarter earnings update. In its FY25 communication, the company said the board had recommended a dividend of ₹4 per share, linking the payout to the year’s operating performance.

Q4FY25 results: profit and revenue trend

For Q4 FY25 ended March 31, 2025, Strides reported a sharp year-on-year rise in profitability on the back of higher revenue and better operating leverage. Consolidated revenue for the quarter came in at ₹11,904 million, up 17.0% YoY. The company reported operational profit after tax (PAT) of ₹1,130 million, compared with ₹242 million a year earlier, reflecting a near five-fold rise. EBITDA for the quarter rose 22.0% to ₹2,179 million, and EBITDA margin expanded 75 basis points to 18.3%.

FY25 performance: profit surged, margins improved

For the full year FY25, Strides reported consolidated revenue of ₹45,653 million, a 17.2% YoY increase. Operational PAT rose to ₹3,447 million, described as a 12x increase year-on-year, while operational EPS increased to ₹37.5. Full-year EBITDA increased 36.8% to ₹8,028 million, and the EBITDA margin improved 252 basis points to 17.6%. The company also reported gross margin of ₹25,854 million for FY25.

US business: launches and base portfolio supported growth

Strides highlighted continued momentum in the US market during FY25. US revenue for the full year was $191 million, up 21.8% YoY, and the company said this exceeded its outlook. For the March quarter, US revenue was $17 million, supported by new product launches and a stable base business. Management commentary in the results release attributed performance to commercial execution and a stronger product contribution.

Debt position: net debt reduction featured in management commentary

Alongside earnings, the company highlighted balance-sheet improvement in FY25. Management said net debt reduced by ₹5,128 million, and the net debt-to-EBITDA ratio improved to 1.9x. The company linked this to financial discipline over the year, in addition to operating profit growth.

What the company said about the ₹4 dividend

In its FY25 update, Strides said the board had recommended a dividend of ₹4 per share for FY25, reflecting the year’s performance. The separate dividend line in the provided data states the company declared a dividend of ₹4.00 on 22 July 2025. The announcement came after the FY25 results, when profitability and margins showed a meaningful improvement versus the prior year.

Market reaction: stock rose on profit surge headline

Newsflow around the March-quarter results also captured an immediate stock reaction. A Reuters item noted Strides Pharma shares rose 2.4% to ₹709 after results, while highlighting that Q4 consolidated net profit jumped nearly five-fold year-on-year. The same report added the stock was up about 5.5% year-to-date, and was attempting to extend gains for a fourth session.

Key financial snapshot (all INR figures in ₹ million)

Background: earlier dividend references in older filings

The provided material also includes older performance commentary from FY20, including references to Ranitidine withdrawal impacts and a separate dividend discussion for that year. Those FY20 disclosures cited adjusted revenues of ₹29,127 million and adjusted EBITDA of ₹6,514 million, along with mention of a higher dividend figure for that period. However, the current financial year dividend referenced in the FY25 results cycle is ₹4 per share, and that is the payout linked to the FY25 board recommendation and the July 2025 declaration date.

Why this matters for investors tracking payouts

For dividend-focused investors, the key takeaway is clarity on the payout amount and the operating context. FY25 showed higher revenue, stronger EBITDA growth than revenue, and margin expansion, while management also highlighted debt reduction and a lower leverage ratio. In that setting, a ₹4 per share dividend signals that Strides is pairing operating improvement with shareholder returns. Investors typically also track whether such payouts remain consistent with cash generation and debt targets, and Strides’ FY25 commentary put both profitability and deleveraging in focus.

Conclusion

Strides Pharma Science’s FY25 dividend is ₹4 per share, declared on 22 July 2025, alongside a year marked by higher revenue, improved margins, and strong growth in operational profit. Next updates to watch include the company’s subsequent board and shareholder approvals and any further guidance linked to product launches and regulated-market performance.